Efficacy and Concentration-Response of Murine Anti-VEGF Monoclonal Antibody in Tumor-Bearing Mice and Extrapolation to Humans

• Published in: Toxicologic pathology 1999-01, Vol.27 (1), p.14-21
• Main Authors: Mordenti, Joyce, Thomsen, Karen, Licko, Vojtech, Chen, Helen, Gloria Meng, Y., Ferrara, Napoleone
• Format: Article
• Language: English
• Subjects: Animals; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - pharmacology; Biological and medical sciences; Cell Division - drug effects; Dose-Response Relationship, Drug; Drug toxicity and drugs side effects treatment; Endothelial Growth Factors - immunology; Female; Growth Inhibitors - blood; Growth Inhibitors - pharmacokinetics; Growth Inhibitors - pharmacology; Humans; Lymphokines - immunology; Medical sciences; Mice; Mice, Nude; Neoplasm Transplantation; Pharmacology. Drug treatments; Recombinant Proteins - blood; Recombinant Proteins - pharmacokinetics; Recombinant Proteins - pharmacology; Rhabdomyosarcoma - immunology; Rhabdomyosarcoma - pathology; Rhabdomyosarcoma - therapy; Toxicity: cardiovascular system; Transplantation, Heterologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors
• ISSN: 0192-6233; 1533-1601
• DOI: 10.1177/019262339902700104

The development of a neovascular supply (angiogenesis) is a major aspect of tumorigenesis. Recent work has indicated that vascular endothelial growth factor (VEGF) is a major regulator of angiogenesis. In vitro and in vivo studies have demonstrated that an anti-VEGF antibody is capable of suppressing the growth of human tumor cell lines. The following study was conducted in tumor-bearing nude mice to evaluate the concentration-response relationship of murine anti-VEGF monoclonal antibody (muMAb VEGF) so that an efficacious plasma concentration of the recombinant humanized form (rhuMAb VEGF) in cancer patients could be estimated. (This study was included in our Investigational New Drug application to support the clinical dosing regimen and projected human safety factors for the toxicology program.) Additionally, the growth dynamics of the tumors were evaluated as a function of dose to explore whether a mechanismic interpretation of tumor growth inhibition by muMAb VEGF is possible. On day 1, A673 human rhabdomyosarcoma cells (2 X 106 cells/mouse) were injected subcutaneously in 188 beige nude mice (16-24 g). Treatment with muMAb VEGF (0.05-5.0 mg/kg; n = 24/group), phosphate-buffered saline (n = 10), or anti-gp120 isotype-matched control antibody (5.0 mg/kg; n =10) began 24 hr later. Each animal received intraperitoneal injections of test material twice weekly for 4 wk. Immediately prior to each dose, 2 mice from each muMAb VEGF group were selected randomly, and plasma was collected for pharmacokinetic evaluation; at the end of the study, samples were collected from all animals for pharmacokinetic evaluation. Tumor dimensions were recorded weekly, and at the end of the study, tumor weight and dimensions were recorded. Satisfactory tumor suppression in nude mice was achieved at muMAb VEGF doses of ≥2.5 mg/kg, where the average trough muMAb VEGF plasma concentration was 30 μg/ml (concentrations in individual animals >10 μg/ml). Assuming the pharmacokinetics of rhuMAb VEGF in patients will resemble the pharmacokinetics of a similar humanized anticancer monoclonal antibodies, a clinical dosing regimen was designed to maintain the rhuMAb VEGF plasma concentration in this efficacious range. This study shows an approach that can be used to estimate a human dosing regimen from preclinical pharmacokinetic/pharmacodynamic data. Because we have just initiated clinical trials with rhuMAb VEGF, we cannot judge clinical outcome in relation to these preclinical prediction